Shouldn't MDAI + L-Deprenyl (MAO-B inhibitor) = MDMA-like damage to 5-HT receptors?
Question:
Shouldn't MDAI + L-Deprenyl (MAO-B inhibitor) = MDMA-like damage to 5-HT receptors?
There is conflicting data on this point that I would like help in parsing, if any one here has the time/inclination/knowledge.
Earlier in this thread someone mentioned the white paper:
http://www.erowid.org/references/refs_view.php?A=ShowDoc1&ID=691
I'll quote the relevant bits to establish some premise:
Pretreatment with either clorgyline or deprenyl before MDAI resulted in a dopaminergic profile similar to that seen after MDMA. More specifically, the combination produced increases in DA and decreases in DA metabolites, as contrasted with the increases in both DA and its metabolites seen with MDAI alone. [...] The monoamine profile after deprenyl plus MDAI gave the closest similarity to that seen after MDMA alone.
However, neither the clorgyline nor the deprenyl pretreatments before MDAI resulted in any significant decrease in the levels of 5-HT at 1 week after dosing.
[...]
The DOPAC/DA ratio can be altered by a number of agents, including: MAO inhibitors [such as L-Deprenyl], DA uptake inhibitors, and nonvesicular DA releasers. [...] ...if this DOPAC/DA ratio was a key indicator of the neurotoxic effects of MDMA, treatment with agents that decrease this ratio in combination with a non-neurotoxic MDMA analogue such as MDAI, should result in a short-term mono-amine profile similar to that seen with MDMA. [therefore this combination might result in MDMA-like neurotoxicity]
From what I understand, MDAI is not toxic because it has no affinity for dopaminergic synapses. This paper seems to believe the DOPAC/DA ratio is the key to why MDAI (when taken alone) is a non-neurotoxic
releasing agent. It theorizes that MDAI + [Increased Dopamine Activity] should cause neurotoxicity similar to MDMA.
Yet this same paper also relates that MDAI + L-Deprenyl as a combination, which
should feel subjectively very similar to taking MDMA, appears to have zero long-term serotonin receptor damage. MDAI + amphetamine, on the other hand,
does cause MDMA-like neurotoxicity. L-Deprenyl seems inexplicably exempt from the rule.
It is already documented that L-Deprenyl, a
dopamine-increasing substance (among other MAO-B effects), counter-intuitively works to help reduce the amount of MDMA serotonin receptor damage.
A Google search on L-Deprenyl's effects on the DOPAC/DA ratio yields talk of neuroprotective effects that are supposed to help maintain this ratio while under attack by neurotoxic releasing agents, such as PMA/MDMA/etc.
Also (from the wiki):
Antioxidants such as ascorbic acid and MAO-B inhibitors like selegiline [i.e. L-Deprenyl], [...] are neuroprotective, and can fully block the damage induced by neurotoxic releasing agents.
Here, L-Deprenyl is specifically mentioned as being a general neuroprotective tool against neurotoxic releasing agents.
_________________________________________________
My
one personal experience taking [100mg MDAI as a base] while on 5mg of L-Deprenyl is that it feels too good to believe doses once every 12 hours over 4 days (as was done in the white paper's study) could
not be neurotoxic...
Yet that's what this data would appear to suggest
Perhaps I just read something wrong somewhere along the way? If not, I would call this possibly one of the greatest nontoxic, long-term anti-depressant combinations discovered by human kind...
The fact that it dilates your pupils for up to 6 or 7 hours is another indicator to me that long-term use
should cause problems. But again, the data appears to conflict on this point.
Yet you do indeed remain clear-headed while on it, and there is no hint of hangover or physical or mental strain during or after the experience... Heart-rate doesn't seem to change either. So I'm really at a loss how to interpret the dangers of MDAI + L-Deprenyl.